CSL secures lixudebart licensing deal with Alentis for 355 million dollars
October 06, 2026 | 10:19
Biopharmaceutical firm CSL paid 355 million US dollars upfront to Alentis to commercialise lixudebart, pledging up to 1.2 billion US dollars in milestone payments for rare disease therapies.
Mobile Version